{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T07:27:24Z","timestamp":1759390044646,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,3,16]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>A woman in her 30s with a medical history of metastatic rectal adenocarcinoma, currently on pembrolizumab, which started a few weeks ago, was admitted for abdominal pain. During the hospital stay, she experienced sharp chest pain. Troponin was 1885 ng\/mL which peaked at 7338 ng\/mL. ECG was unremarkable. The echocardiogram showed an Ejection fraction (EF) of 55%\u201360% and basal-inferior wall hypokinesis. Left heart catheterisation showed no coronary abnormalities. Cardiac MRI showed a non-coronary area of focal T1 and T2 hyperintense signal and transmural delayed gadolinium enhancement in the mid-basal inferior\/inferoseptal wall consistent with myocardial damage. Pericardium showed increased thickness and adhesions at the right ventricular outflow tract consistent with pericarditis. Steroid therapy was initiated, and a marked clinical response was achieved. Immune checkpoint inhibitor-induced myocarditis and pericarditis is a rare complication associated with a high mortality rate, if untreated. Diagnosis requires a multidisciplinary approach, and early detection is critical to preventing a fatal outcome.<\/jats:p>","DOI":"10.1136\/bcr-2023-259497","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T13:00:26Z","timestamp":1711026026000},"page":"e259497","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Immune checkpoint inhibitor-induced myopericarditis"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-7737","authenticated-orcid":false,"given":"Mohamed","family":"Alrayyashi","sequence":"first","affiliation":[{"name":"Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Uddin","sequence":"additional","affiliation":[{"name":"Cardiology, Wayne State University, Warren, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Bdiwi","sequence":"additional","affiliation":[{"name":"Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Afonso","sequence":"additional","affiliation":[{"name":"Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"2025082723453329000_17.3.e259497.1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-Checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025082723453329000_17.3.e259497.2","first-page":"96","article-title":"Keytruda (Pembrolizumab): first PD-1 inhibitor approved for previously treated Unresectable or metastatic Melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"2025082723453329000_17.3.e259497.3","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune Checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2025082723453329000_17.3.e259497.4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune Checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025082723453329000_17.3.e259497.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571"},{"key":"2025082723453329000_17.3.e259497.6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205218","article-title":"Cardiac toxicity associated with immune Checkpoint inhibitors: A systematic review","volume":"13","author":"Shalata","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025082723453329000_17.3.e259497.7","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jtho.2019.02.026","article-title":"Immune Checkpoint inhibitor-associated Pericarditis","volume":"14","author":"Altan","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025082723453329000_17.3.e259497.8","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/cam4.5050","article-title":"Immune Checkpoint inhibitor induced myocarditis, myasthenia gravis, and Myositis: A single-center case series","volume":"12","author":"Longinow","year":"2023","journal-title":"Cancer Med"},{"key":"2025082723453329000_17.3.e259497.9","article-title":"Immune Checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases","volume":"7","author":"Matzen","year":"2021","journal-title":"Cardiooncology"},{"key":"2025082723453329000_17.3.e259497.10","doi-asserted-by":"crossref","first-page":"770631","DOI":"10.3389\/fphar.2021.770631","article-title":"Case series of steroid-resistant immune Checkpoint inhibitor associated myocarditis: A comparative analysis of corticosteroid and tofacitinib treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025082723453329000_17.3.e259497.11","first-page":"157","article-title":"Management of immune Checkpoint inhibitor\u2013induced myocarditis","volume":"3","author":"Thuny","year":"2021","journal-title":"JACC: CardioOncology"},{"key":"2025082723453329000_17.3.e259497.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.072"},{"key":"2025082723453329000_17.3.e259497.13","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcr\/ytab478","article-title":"Paaladinesh Thavendiranathan, immune Checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated cardiovascular magnetic resonance Lake Louise criteria","volume":"6","author":"Wintersperger","year":"2022","journal-title":"Eur Heart J Case Rep"},{"key":"2025082723453329000_17.3.e259497.14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune Checkpoint inhibitor-associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"2025082723453329000_17.3.e259497.15","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jacc.2021.01.043","article-title":"CMR parametric mapping in immune Checkpoint inhibitor myocarditis: novel noninvasive tools in a lethal condition","volume":"77","author":"Kramer","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-259497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:45:47Z","timestamp":1756363547000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-259497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,21]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bcr-2023-259497"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-259497","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}